Ninety jobs lost as Cork pharma firm Corden to close plant
Management at the 20-acre Little Island plant have blamed a number of factors for the decision, including current market conditions for its active pharmaceutical ingredient products, the limited potential for the development and commercialisation of new products, the scale of the plant and the significant capital investment necessary for it.
“The decision to cease manufacturing does not in any way reflect on the staff at the company which ICIG acquired three years ago, but is a reflection of very difficult market conditions and the plant’s long-term commercial prospects,” a spokesman said.
